Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sensitivity, Specificity, and Predicted Value01:13

Sensitivity, Specificity, and Predicted Value

1.5K
In healthcare diagnostics, laboratory tests play a crucial role in identifying and diagnosing a wide range of medical conditions. However, interpreting test results is not always straightforward. An abnormal test result does not always confirm the presence of a disease, just as a normal result does not guarantee its absence. To assess the reliability of these diagnostic tools, healthcare practitioners rely on two key statistical indicators: sensitivity and specificity.
Sensitivity is the...
1.5K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

503
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
503
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

2.0K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.0K
Pharmacovigilance01:19

Pharmacovigilance

1.8K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.8K
Drug Regulation01:25

Drug Regulation

3.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.2K
Hazard Ratio01:12

Hazard Ratio

659
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
659

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improving bioethics by clarifying and elaborating its methodology: a response to Gomez-Virseda and colleagues.

Medicine, health care, and philosophy·2026
Same author

The Biases of Moving from Consciousness to Intelligence.

AJOB neuroscience·2026
Same author

Responsive Equanimity to Uncertainty: Towards the Construction of a Concept for Handling Medical Uncertainty in Clinical Practice.

Health care analysis : HCA : journal of health philosophy and policy·2026
Same author

[Illness anxiety disorder].

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same author

Delimiting medicine.

European journal of internal medicine·2026
Same author

Temporal and geographical variations of chest x-rays: A ten-year register study from Norway.

Acta radiologica open·2025
Same journal

Restraint and venous thromboembolism in psychiatric hospitals: understanding risk and prevention.

BMJ (Clinical research ed.)·2026
Same journal

Health costs of the UK-US trade deal on pharmaceuticals.

BMJ (Clinical research ed.)·2026
Same journal

Death of 8 year old after assessment by advanced practitioner triggers coroner's warning for GPs.

BMJ (Clinical research ed.)·2026
Same journal

The Mann review: Avoiding the risk of asymmetric anti-racism policy.

BMJ (Clinical research ed.)·2026
Same journal

Assessing the early effects of Australia's Social Media Minimum Age Act on adolescent social media use.

BMJ (Clinical research ed.)·2026
Same journal

PMOS: a better name should end the habit of dismissing patients.

BMJ (Clinical research ed.)·2026
See all related articles

Related Experiment Video

Updated: Feb 26, 2026

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

995

New diagnostic tests: more harm than good

Bjørn Hofmann1, H Gilbert Welch2

  • 1Department of Health Sciences in Gjøvik, Norwegian University of Science and Technology, and Centre for Medical Ethics at the University of Oslo, PO Box 1130, Blindern, N-0318 Oslo, Norway b.m.hofmann@medisin.uio.no.

BMJ (Clinical Research Ed.)
|July 20, 2017
PubMed
Summary

No abstract available in PubMed .

More Related Videos

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC

Published on: May 10, 2016

12.8K
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.4K

Related Experiment Videos

Last Updated: Feb 26, 2026

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

995
High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC

Published on: May 10, 2016

12.8K
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.4K